Navigation Links
Success of National Fundraising Event Critical to Promising Research for Life-Threatening Kidney Disease
Date:9/10/2009

KANSAS CITY, Mo., Sept. 10 /PRNewswire-USNewswire/ -- More than 12.5 million children and adults, worldwide, are waiting for a treatment and cure for polycystic kidney disease (PKD), a genetic disorder often causing kidney failure and death. Unfortunately, critical PKD research may be put on hold if fundraising efforts continue to fall short for the Walk for PKD, the PKD Foundation's signature fundraising event.

The Walk for PKD, held each fall in cities across the United States typically raises up to $3 million annually. Much of that money goes straight into research. But all that could change if participation and fundraising don't increase in the next few weeks. The first Walk for PKD events in cities like Boston, Milwaukee, Washington, D.C., San Francisco, Minneapolis and Kansas City are coming up September 12 and 13. Other Walk for PKD events are scheduled throughout the fall.

"There are now clinical trials for PKD, including those aimed at helping children with the disease, and several drugs showing promise as potential treatments," said Dan Larson, PKD Foundation President and CEO. "All that's needed now is funding. The Walk for PKD is an easy and meaningful way to provide help and hope to the millions, worldwide, with PKD."

For find a Walk for PKD near you and support research needed to find a treatment and cure for PKD, visit www.pkdcure.org or call 1-800-PKD-CURE. Registration is easy and free. To help drive fundraising, PKD leaders are asking all registrants to ask 20 friends for $20 each.

PKD causes cysts to grow on the kidneys, eventually leading to kidney failure. Dialysis and transplantation are the only treatments for kidney failure. There is no cure for PKD. The PKD Foundation is the only organization, worldwide, fighting PKD through research, education, advocacy, support and awareness. Learn more at

SOURCE PKD Foundation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Kenyan malaria success strengthens call for free insecticide-treated nets for all
2. Eligard(R) six-month formulation successfully completes European approval procedure
3. The Pharma & Life Sciences Best Practice Database: an Industry Resource for Successful Techniques and Performance Benchmarks for Reaching the Top
4. Milestone Scientific Announces Successful Completion of its Collaboration Agreement With Carticept Medical
5. Texas Largest Physician Carrier Announces 5th Successive Rate Cut on Anniversary of Lawsuit Reform
6. Bacteria successful in cancer treatment
7. Congress Poised to Add Millions of Uninsured Children to Successful, Bipartisan Health Plan
8. Success of Shape-Up Somerville Childhood Obesity Intervention to be Presented at the Friedman School Symposium at Tufts, October 29-31, 2007 - Boston
9. Success of Shape Up Somerville childhood obesity intervention to be presented
10. Cell growth technology promises more successful drug development
11. CIGNA Group Insurance Celebrates Return to Work Success During National Rehabilitation Awareness Week
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:ThermoGenesis Announces Agreement for Adipose Tissue Clinical Program 2ThermoGenesis Announces Agreement for Adipose Tissue Clinical Program 3ThermoGenesis Announces Agreement for Adipose Tissue Clinical Program 4VidaySalud.com(TM) Reaches 1,000,000 Page Views In its First Six Months of Operation 2Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 2Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 3Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 4Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 5Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 6Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 7Research Reveals How Mitochondrial Gene Defects Impair Respiration Other Major Life Functions 58280 1Research Reveals How Mitochondrial Gene Defects Impair Respiration Other Major Life Functions 58280 2Research Reveals How Mitochondrial Gene Defects Impair Respiration Other Major Life Functions 58280 3Encouraging HIV AIDS Vaccine Trial Results Support GeoVax Labs Inc Strategy 14265 1Encouraging HIV AIDS Vaccine Trial Results Support GeoVax Labs Inc Strategy 14265 2Encouraging HIV AIDS Vaccine Trial Results Support GeoVax Labs Inc Strategy 14265 3Encouraging HIV AIDS Vaccine Trial Results Support GeoVax Labs Inc Strategy 14265 4Reportlinker Adds In Vitro Diagnostics in a Recession 3A IVD Market Forecasts Analysis and Success Strategies Report 14260 1Reportlinker Adds In Vitro Diagnostics in a Recession 3A IVD Market Forecasts Analysis and Success Strategies Report 14260 2Reportlinker Adds In Vitro Diagnostics in a Recession 3A IVD Market Forecasts Analysis and Success Strategies Report 14260 3Reportlinker Adds In Vitro Diagnostics in a Recession 3A IVD Market Forecasts Analysis and Success Strategies Report 14260 4Reportlinker Adds In Vitro Diagnostics in a Recession 3A IVD Market Forecasts Analysis and Success Strategies Report 14260 5Reportlinker Adds In Vitro Diagnostics in a Recession 3A IVD Market Forecasts Analysis and Success Strategies Report 14260 6Reportlinker Adds In Vitro Diagnostics in a Recession 3A IVD Market Forecasts Analysis and Success Strategies Report 14260 7Reportlinker Adds In Vitro Diagnostics in a Recession 3A IVD Market Forecasts Analysis and Success Strategies Report 14260 8Reportlinker Adds In Vitro Diagnostics in a Recession 3A IVD Market Forecasts Analysis and Success Strategies Report 14260 9